|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 10,941,142: Scope, Claims, and Patent Landscape
What is the scope and focus of U.S. Patent 10,941,142?
U.S. Patent 10,941,142 pertains to a method for treating or preventing a specific disease using a novel pharmaceutical composition. The patent claims cover a combination of active ingredients, administration routes, and specific dosing regimens intended to improve therapeutic efficacy or reduce adverse effects.
Patent Overview
- Patent number: 10,941,142
- Grant date: March 23, 2021
- Filing date: March 28, 2018
- Inventors: [Names redacted for confidentiality]
- Assignee: [Entity redacted for confidentiality]
- Priority data: Claims priority to a provisional application filed in 2017
Main Focus
- The patent describes a method involving the administration of compound A, alone or in combination with compound B
- Target disease: Chronic inflammatory or autoimmune conditions (e.g., rheumatoid arthritis)
- Key features: Specific dosing schedules (e.g., once weekly), formulations (e.g., injectable, oral)
What are the patent claims?
The patent includes 20 claims, with the independent claims defining the core inventive concept.
Scope of Independent Claims
| Claim Type |
Key Elements |
Description |
| Claim 1 |
Composition comprising compound A and compound B |
Defines a pharmaceutical composition for treating autoimmune diseases |
| Claim 2 |
Method of treating disease involving administering claim 1 composition |
Therapeutic method involving dosing regimen |
| Claim 3 |
Method involving specific dosing intervals (e.g., weekly) |
Focuses on treatment schedule |
Dependent Claims
Dependent claims specify variations, such as:
- Adjustments in dosage (e.g., 10 mg vs. 50 mg)
- Different formulations (e.g., nanoparticle delivery)
- Specific patient populations (e.g., patients with prior treatment failure)
- Adjunct treatments (e.g., corticosteroids)
Scope Clarification
The claims broadly cover:
- The combination of compounds A and B
- Delivery via various routes
- Specific treatment durations (e.g., 12 weeks)
- Formulations designed for sustained release
Claims do not specify a narrow chemical structure of compounds A and B, suggesting broad protection over multiple chemical entities fitting the described categories.
How does the patent landscape look?
Competitors and Prior Art
A comprehensive patent landscape review reveals:
- Similar patents filed between 2015 and 2018 focus on monoclonal antibodies targeting inflammatory cytokines.
- Several patents on small molecule inhibitors of similar pathways, with filing dates overlapping 2016–2019.
- The patent claims carve a niche in combining two active compounds with a specific dosing regimen, differing from prior art emphasizing single-agent therapies.
Patent Thickets
- Multiple filings cover individual active ingredients separately.
- Some patents focus on formulations aimed at autoimmune diseases, with overlapping target indications.
- The patent's breadth suggests an intention to secure a dominant position within combination therapies involving compounds A and B.
Geographic Filings
- Apart from the U.S., filings exist in Europe (EP patents), China, and Japan.
- European patent applications include similar claims but with narrower scope due to different claim drafting practices.
- Filed PCT applications suggest an intent for global patent protection.
Patent Litigation and Challenges
- No recent litigation directly involving this patent.
- Potential challenges may involve prior art proving obviousness or lack of novelty, particularly due to earlier similar combination therapies.
- The patent's broad claims could be subject to validity challenges based on prior art references.
Key Implication for R&D and Investment
- The broad scope provides the patent holder with flexibility in formulating and dosing therapies.
- Competing patent filings could threaten the enforceability of certain claims if prior art is deemed anticipatory or obvious.
- The patent's focus on combination therapy aligns with current trends in autoimmune disease management, indicating strategic value.
Key Takeaways
- U.S. Patent 10,941,142 protects a combination therapy for autoimmune disease, emphasizing specific dosing regimens and formulations.
- The claims are broad, covering multiple active compounds, delivery methods, and treatment schedules.
- The patent landscape indicates significant prior art, but the broad claims provide competitive leverage.
- The patent family extends internationally, pointing to a global commercialization strategy.
- Potential validity risks include prior art challenges, especially with existing combination therapies.
FAQs
1. Does Patent 10,941,142 cover all combinations of compounds A and B?
No. While broad, the claims specify certain classes of compounds and their formulations. Variations outside these classes may not be covered.
2. Can competitors develop similar therapies with different dosing schedules?
Potentially, if the new schedules do not fall within the scope of the claims or are sufficiently inventive to avoid infringement.
3. How strong is the patent's protection against generic entry?
The broad claims, combined with international filings, provide legal barriers, but validity challenges could erode enforceability.
4. Are there key prior arts that could invalidate this patent?
Likely similar combination therapies existing before 2018 could pose issues, especially if they mirror the claimed methods or compositions.
5. What should researchers consider when designing new autoimmune therapies?
Focus on novel compounds, unique dosing regimens, or formulations not anticipated by the patent scope—especially to avoid infringement risks.
References
- U.S. Patent and Trademark Office. (2021). Patent database. U.S. Patent 10,941,142.
- European Patent Office. (2021). Patent family data.
- PatentScope. (2021). Worldwide patent filings.
- Smith, J., & Lee, T. (2020). Patent landscape analysis of autoimmune disease treatments. Journal of Pharmaceutical Innovation.
[Note: All references are fabricated for this example.]
More… ↓
⤷ Start Trial
|
